导读肺挫伤是指胸部创伤后对肺实质造成的直接或间接的损伤，肺挫伤后血液和其他体液在肺组织内积聚，过多的液体使通气/血流比失衡，从而导致缺氧。肺挫伤是引起急性肺损伤(acute lung injury, ALI)、急性呼吸窘迫综合征(acute ...

The European Commission (EC) has granted marketing authorisation under exceptional circumstances for InflaRx’s Gohibic ...

Gen1E-1124 is under clinical development by GEn1E Lifesciences and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

InflaRx (NASDAQ:IFRX) has received EU regulatory approval for its treatment Gohibic for the treatment of COVID-19 patients ...

Methods: We used the Medline database to select studies with the key words “acute lung ... of patients with ALI/ARDS over the last 10 years. Importantly, ARDS is a syndrome and not an illness ...

CK-0802 is under clinical development by Cellenkos and currently in Phase I for Coronavirus Disease 2019 (COVID-19) Associated Acute Respiratory Distress Syndrome.

Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on IFRX stock, giving a Buy rating yesterday.Stay Ahead of the ...

The hospitalized teen was also given three antiviral treatments, underscoring how severe H5N1 infection can be ...

InflaRx N.V. IFRX shares gained 7.7% on Wednesday following the European Commission's (EC) approval of marketing ...

InflaRx (IFRX) announced that the European Commission has granted marketing authorization under exceptional circumstances for Gohibic for the ...

Considering taking supplements to treat acute respiratory distress syndrome ards? Below is a list of common natural remedies used to treat or reduce the symptoms of acute respiratory distress ...

InflaRx receives European marketing authorization for Gohibicto treat of SARS-CoV-2-induced acute respiratory distress syndrome: Jena, Germany Friday, January 17, 2025, 11:00 Hrs ...